Drugs / OMT-28
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03078738 | Feb 2017 → Mar 2018 | — | Omeicos Therapeutics GmbH | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05972954 | May 2023 → May 2025 | mitochondrial disease | Omeicos Therapeutics GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03906799 | Mar → Nov 2019 | atrial fibrillation | Omeicos Therapeutics GmbH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-01-29 | Omeicos Therapeutics GmbH | Results OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD) omeicos.com ↗
The study results demonstrate OMT-28’s therapeutic potential to improve the physical condition in PMD based on significant recovery of the impaired mitochondrial fitness in the responding patients. |
| 2024-09-26 | Omeicos Therapeutics GmbH | Results OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease omeicos.com ↗
Initial data analysis confirms the strong safety profile and very good tolerability of OMT-28 in the target population. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMT-28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078738 ↗ |
| Modality | Small molecule | “fully synthetic small molecule” NCT03078738 ↗ |
| Route | Oral | “Single dose of OMT-28 (4 mg) Oral” NCT03078738 ↗ |